


FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
760100.450APPLICATION NO.
09/729,644

INFORMATION DISCLOSURE STATEMENT

(See Remarks sheets if necessary)

APPLICANTS
Glenn Pierce and Lois Ann ChandlerFILING DATE
November 30, 2000GROUP ART UNIT
~~1632~~/636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						

RECEIVED

MAR 30 2001

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
					YES NO
	AD				
	AE				
	AF				

TECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DS	AG	Dwarki et al., "Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII <i>in vivo</i> in mice," <i>Proceedings of the National Academy of Science USA</i> 92: 1023-1027, February 1995.
DS	AH	Naffakh et al., "Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts," <i>Proceedings of the National Academy of Science USA</i> 92: 3194-3198, April 1995.
DS	AI	Thompson et al., "Heparin-binding growth factor 1 induces the formation of organoid neovascular structures <i>in vivo</i> ," <i>Proceedings of the National Academy of Science USA</i> 86: 7928-7932, October 1989.
	AJ	
	AK	
	AL	
	AM	
	AN	
	AO	
	AP	


EXAMINER

Daryl Sullen

DATE CONSIDERED

11/20/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 760100.450	APPLICATION NO. 09/729,644
 <p>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>		APPLICANTS Glenn Pierce and Lois Ann Chandler	
		FILING DATE November 30, 2000	GROUP ART UNIT 1632 / 636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
DS	AK	WO 97/38729	10/23/97	WIPO		
DS	AL	WO 99/58656	11/18/99	WIPO		
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	
	AQ	
	AR	


EXAMINER



DATE CONSIDERED

8/1/02

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
760100.450APPLICATION NO.
09/729,644SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Glenn Pierce and Lois Ann Chandler

FILING DATE

November 30, 2000

GROUP ART UNIT

1632-1636

FEB 20 2002
TECH CENTER 1600/2800

RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AS	AP	Régulier et al., "Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts," <i>Gene Therapy</i> 5: 1014-1022, 1998.
	AQ	
	AR	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).